Grifols, S.A. (LON:0RDU)

Market Cap	4.45B
Revenue (ttm)	5.96B
Net Income (ttm)	129.77M
Shares Out	n/a
EPS (ttm)	0.19
PE Ratio	34.27
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,404,589
Average Volume	356,739
Open	8.20
Previous Close	8.27
Day's Range	7.99 - 8.24
52-Week Range	5.27 - 13.18
Beta	0.92
RSI	47.72
Earnings Date	May 5, 2025

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1909
• Employees: 23,833
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RDU

Financial Performance

In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.

Financial numbers in EUR